Le Lézard
Classified in: Health
Subject: RCL

Food Recall Warning (Allergen) - Q One Homemade brand Blackrice & Honey Hoddeok Mix recalled due to undeclared peanut


Product photos are available: https://recalls-rappels.canada.ca/en/alert-recall/q-one-homemade-brand-blackrice-honey-hoddeok-mix-recalled-due-undeclared-peanut 

OTTAWA, ON, Feb. 11, 2022 /CNW/ - 

Summary

Affected product

Brand

Product

Size

UPC

Codes

Q One
Homemade

Blackrice & Honey
Hoddeok Mix

400 g

8 801013 797596

All codes where peanut is
not declared on the label

Issue

Korea Food Trading Ltd. is recalling Q One Homemade brand Blackrice & Honey Hoddeok Mix from the marketplace because it contains peanuts which are not declared on the label.

The recalled product has been sold in Ontario and Quebec.

What you should do

Learn more:

Background

This recall was triggered by a consumer complaint.

There has been one reported reaction associated with the consumption of this product.

What is being done

The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated food recall warnings.

The CFIA is verifying that industry is removing recalled products from the marketplace.

Également disponible en français

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: